New schizophrenia drug enters final safety testing phase
NCT ID NCT07369154
Summary
This study is testing the long-term safety of a medication called LB-102 for adults with stable schizophrenia. It's for people who aren't satisfied with their current antipsychotic medication due to side effects or effectiveness issues and want to switch treatments. The study will follow 900 participants for 52 weeks to see how well they tolerate the medication and monitor for any safety concerns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.